You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-Lymphocyte-activation gene 3 Pathway (LAG-3)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in

Not yet recruiting
  • Brain Ischemia
  • Serum Iron
  • +7 more
  • Aswan, Egypt
    Aswan University Hospital
Mar 7, 2023

Tumors by Site Trial in Worldwide (Relatlimab, Nivolumab, BMS-986213)

Active, not recruiting
  • Neoplasms by Site
  • Relatlimab
  • +2 more
  • La Jolla, California
  • +52 more
Feb 10, 2022

Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial

Not yet recruiting
  • Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • Biospecimen Collection
  • +7 more
  • (no location specified)
Aug 10, 2023

Advanced Cancer Trial in Chengdu, Hangzhou (TQB2223 injection+ Penpulimab Injection)

Recruiting
  • Advanced Cancer
  • TQB2223 injection+ Penpulimab Injection
  • Chengdu, Sichuan, China
  • +1 more
Jun 7, 2023

Nasopharyngeal Carcinoma Trial (procedure, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Biospecimen Collection
  • +9 more
  • (no location specified)
Sep 12, 2023

Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma Trial in New York, Houston (biological, other, procedure)

Active, not recruiting
  • Cutaneous Melanoma
  • +10 more
  • Ipilimumab
  • +4 more
  • New York, New York
  • +1 more
Aug 25, 2021

Solid Tumors, Metastatic Melanoma, NSCLC Trial in Worldwide (RO7247669)

Recruiting
  • Solid Tumors
  • +3 more
  • San Diego, California
  • +20 more
Aug 19, 2022

Advanced Malignant Tumors(Stage IA-IB) Trial in Beijing (AK129 IV infusion)

Not yet recruiting
  • Advanced Malignant Tumors(Stage IA-IB)
  • AK129 IV infusion
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Science
Jan 17, 2023

Solid Tumor, Adult Trial (EOC202, albumin-bound paclitaxel)

Not yet recruiting
  • Solid Tumor, Adult
  • EOC202
  • albumin-bound paclitaxel
  • (no location specified)
Apr 7, 2022

Melanoma Trial in Orlando, Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Orlando, Florida
  • +1 more
Jul 5, 2022

Extramembranous Glomerulopathy Trial in Nice (Blood sample)

Recruiting
  • Extramembranous Glomerulopathy
  • Blood sample
  • Nice, France
    Centre Hospitalier Universitaire de Nice
Jun 20, 2022

Squamous Cell Carcinoma of the Head and Neck Trial in Pittsburgh (Nivolumab+Relatlimab, Nivolumab+Ipilimumab)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 13, 2022

Stage II Melanoma Trial in Wollstonecraft (Relatlimab and nivolumab fixed dose combination (FDC))

Not yet recruiting
  • Stage II Melanoma
  • Relatlimab and nivolumab fixed dose combination (FDC)
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Oct 26, 2022

CORONAVIRUS INFECTIONS Trial (anti-SARS-Cov-2 vaccination)

Not yet recruiting
  • CORONAVIRUS INFECTIONS
  • anti-SARS-Cov-2 vaccination
  • (no location specified)
Dec 15, 2022

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Klotho _ LRP-6 _ Gastric Adenocarcinoma

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Prognostic study
  • (no location specified)
Jan 29, 2023

TIA, Carotid Artery Plaque, Carotid Atherosclerosis Trial in Cambridge (Interleukin-2 [IL-2], Standard care - Carotid

Not yet recruiting
  • TIA
  • +2 more
  • Interleukin-2 [IL-2]
  • Standard care - Carotid Endarterectomy
  • Cambridge, Cambridgeshire, United Kingdom
    Addenbrookes Hospital
Aug 2, 2023

ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma Trial in Houston (Ipilimumab,

Recruiting
  • ALK Gene Rearrangement
  • +11 more
  • Ipilimumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2020

Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Recruiting
  • Rheumatoid Arthritis
  • Upadacitinib <15 MG [Rinvoq]
  • Montpellier, France
    CHU de Montpellier
Jan 12, 2022

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Migraine Disorders, Chronic Migraine, Episodic Migraine Trial in Pavia (Monoclonal antibody targeting the CGRP pathway (ligand

Recruiting
  • Migraine Disorders
  • +2 more
  • Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
  • Pavia, Italy
    Headache Science & Neurorehabilitation Center
Nov 23, 2023

Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations Trial in Parkville (Alpelisib,

Not yet recruiting
  • Slow-Flow Vascular Malformation
  • +17 more
  • Parkville, Victoria, Australia
    The Royal Children's Hospital
Aug 7, 2023

NSCLC Trial in Canada, United States (Nivolumab, Carboplatin, Paclitaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • Baltimore, Maryland
  • +4 more
Jul 26, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023